Merck & Co., Inc. (BIT:1MRKX)

Market Cap	184.78B
Revenue (ttm)	54.17B
Net Income (ttm)	13.97B
Shares Out	n/a
EPS (ttm)	5.52
PE Ratio	13.23
Forward PE	9.39
Dividend	2.21 (2.90%)
Ex-Dividend Date	Sep 12, 2025

Volume	424
Average Volume	232
Open	76.00
Previous Close	75.60
Day's Range	75.90 - 77.20
52-Week Range	65.40 - 101.20
Beta	n/a
RSI	63.01
Earnings Date	Oct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Pharmaceutical Preparations
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1MRKX

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD